Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C

Bibliography

• Jacobson IM, McHutchison JG, Dusheiko G, Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94
   PubMed Web of Science ®Google Scholar
• Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010;70:147-65
   PubMed Web of Science ®Google Scholar
• Janssen HL, van ZM, Senturk H, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
   PubMed Web of Science ®Google Scholar
• Awad T, Thorlund K, Hauser G, Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51:1176-84
   PubMed Web of Science ®Google Scholar
• Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011;26(Suppl 1):138-43
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Di Iulio J, Ciuffi A, Fitzmaurice K, Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011;53:1446-54
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
   PubMed Web of Science ®Google Scholar
• Di Martino V, Richou C, Cervoni JP, Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; June 14 on line
   PubMedGoogle Scholar
• Langhans B, Kupfer B, Braunschweiger I, Interferon-lambda serum levels in hepatitis C. J Hepatol 2011;54:859-65
   PubMed Web of Science ®Google Scholar
• Barth H. Insights into the role of interferon lambda in hepatitis C virus infection. J Hepatol 2011;54:844-7
   PubMed Web of Science ®Google Scholar
• Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e1000017
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Arora S, Bacon B, Pegylated interferon-lambda shows superior viral response with improved safety and tolerability versus PEGIFNalpha-2A in HCV (G1/2/3/4):emerge phase IIB through week 12. J Hepatol 2011;54:S538-9
   PubMed Web of Science ®Google Scholar
• Bergmann JF, de BJ, Hotho DM, Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 2011;34:443-53
   PubMed Web of Science ®Google Scholar
• Nelson DR, Rustgi V, Balan V, Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 2009;7:212-18
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Sulkowski MS, Lawitz EJ, Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010;139:1257-66
   PubMed Web of Science ®Google Scholar
• Bezemer JM, Grijpma DW, Dijkstra PJ, A controlled release system for proteins based on poly(ether ester) block-copolymers: polymer network characterization. J Control Release 1999;62:393-405
   PubMed Web of Science ®Google Scholar
• De Leede LG, Humphries JE, Bechet AC, Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res 2008;28:113-22
   PubMed Web of Science ®Google Scholar
• Dziublyk I, Yegorova T, Moroz L, Controlled release recombinant human interferon-alpha2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial. J Viral Hepat 2011;18:271-9
   PubMed Web of Science ®Google Scholar
• Bechet A, Verrijk R, Humphries J, Pharmacokinetics, safety, and biomarkers in man after administration of Locteron,a once every two-week controlled release formulation of interferon-alpha. J Hepatol 2006;44:S210
   Web of Science ®Google Scholar
• Lawitz E, Younossi Z, Shiffman ML, Randomized Trial Comparing Systemic and Local Reactions to Controlled-release Interferon Alpha2b and Pegylated-interferon Alpha2b in Hepatitis C Patients Who Failed Prior Treatment. J Hepatol 2009;50:S231
   Web of Science ®Google Scholar
• Krastev Z, Kotzev I, Tchernev K, Randomized, open-label, 12-week comparison of controlled-release interferon alpha 2 b + ribavirin vs. pegylated-interferon alpha 2b in treatment-naive genotype 1 hepatitis C: 4 week results from 480 STUDY (Panel A). J Hepatol 2010;52:S27
   Web of Science ®Google Scholar
• Lawitz E, Younossi Z, Mehra P, SVR for controlled-release Interferon Alpha-2B (CR2b) + Ribavirin Compared to Pegylated Interferon Alpha-2B (PEG2b) + Ribavirin in Treatment-naive Genotype-1 Hepatitis C: final results from SELECT-2. J Hepatol 2011;52:S180-1
   Google Scholar
• Long WA, Younossi ZM, Lawitz E, Timing and frequency of depression during HCV-treatment with controlled-release-IFN2A (CR2B) vs pegylated-IFNA2B (PEG2B): results from SELECT-2, a randomized-open-label-72-week-comparison in 116 treatment-naive patients with genotype-1 HCV. J Hepatol 2011;54:S181-2
   Web of Science ®Google Scholar
• Long WA, Lawitz E, Lurie Y, Adverse event reporting during HCV treatment via weekly clinic visits substantially underestimates flu frequency and severity compared to daily Epro: results from 133 patients in EMPOWER. Hepatology 2010;52:224A
   Google Scholar
• Younossi ZM, Lawitz EJ, Krastev Z, SELECT-2 Clinical Trial Assessing The Efficacy And Saftey Of Controlled-Release Interferon Alpha-2b (CR2b) + Ribavirin (RBV) Versus Pegylated Interferon Alpha-2b (PEG2b) + RBV In Treatment-Naive Genotype-1 (G1) Hepatitis C. Gastroenterology 2011;140:S942
   Web of Science ®Google Scholar